Pharmaceutical commercial strategy has been transformed by the concentration of new product launches in specialty and rare disease categories, the increasing sophistication of payer management requirements, and the proliferation of digital engagement channels. The commercial launch of a major new pharmaceutical product is among the most capital-intensive and strategically consequential undertakings in any industry. A successful oncology launch requires integration of medical affairs, market access, commercial operations, and patient services working in precise coordination across hundreds of hospital accounts and thousands of specialist physicians simultaneously.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Launch Excellence
• Payer Relations and Market Access
• Medical Affairs
• Digital Omnichannel Engagement
• Patient Services and Hub Programs
• Commercial Benchmarking
Table of Contents
1. Executive Summary
2. Landscape Overview
3. Launch Excellence
4. Payer Relations and Market Access
5. Medical Affairs
6. Digital Omnichannel Engagement
7. Patient Services and Hub Programs
8. Commercial Benchmarking
9. Competitive Landscape
10. Strategic Conclusions and Recommendations
11. Appendix
List of Tables
Table 1. Overview and Key Data 2025
Table 2-8. Topic-Specific Analysis Tables
Table 2. Leading Companies — Strategy Assessment 2025
Table 3. Key Risks and Mitigation Strategies
Companies Profiled
Pfizer
Johnson & Johnson
Roche
Novartis
Merck
AstraZeneca
Bristol-Myers Squibb
AbbVie
Eli Lilly
Sanofi
